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Abstract
Radical resection is the only potential cure for patients with locally advanced primary and recurrent rectal cancer and
is considered curative only when the histologic margins are clear of tumour. Early diagnosis of the disease is essential
as it increases the likelihood of a potentially curative resection and prevention of dissemination. Clinical examination,
tumour markers and radiologic modalities such as ultrasonography, computed tomography, magnetic resonance
imaging and positron emission tomography are routinely used in an effort to accurately stage these patients and
provide useful information for the selection of patients for further treatment/management. This review describes the
methods of staging patients with locally advanced primary and recurrent rectal cancer prior to surgery emphasizing
the role that radiologists have in this process.
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Introduction
A number of radiologic modalities are used for the pre-
operative staging of patients diagnosed with recurrent
colorectal cancer within the pelvis in an effort to better
select patients for surgery and medical therapy. This
demonstrates the active role that radiologists have in
this selection. Approximately 11,00014,000 patients
are diagnosed with rectal cancer each year in the
United Kingdom[1] of which up to 16% have locally
advanced tumours[24]. Local recurrence is diagnosed
in about 15% of patients following surgery[5]. Radical
resection is the only potential cure for patients with
locally advanced primary and recurrent rectal cancer
and is considered curative only when the histologic mar-
gins are clear of tumour (R0; 1067% of cases)[6].
Complete tumour resection (R0) can result in 5-year
survival rates of over 35%[7]. However, curative resection
is only feasible when there is no dissemination of the
disease and the tumour invasion at the adjacent struc-
tures is within the limits of resectability.
Therefore early diagnosis of the recurrence is crucial
as it increases the likelihood of curative (R0) resection
and prevention of dissemination. Clinical examination,
tumour markers and radiologic modalities such as ultra-
sonography (US), computed tomography (CT), magnetic
resonance imaging (MRI) and positron emission tomo-
graphy (PET) are routinely used in follow-up, facilitating
this and at the same time helping with the staging and
planning of further treatment/management.
This review describes the methods of staging patients
with recurrent pelvic colorectal cancer prior to surgery,
and demonstrates the input that radiologist have in the
management of these patients. The different radiologic
modalities are also reviewed emphasizing their strengths
and weaknesses.
Methods
A literature search was performed using Medline,
Embase, Ovid and Cochrane databases for studies
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between 1980 and 2010 assessing radiologic modalities
used to stage locally advanced primary and recurrent
rectal cancer. References from each article were also
reviewed. The search was limited to English language
articles. The following keywords and their combination
were used: locally advanced, recurrent, rectal
cancer, local recurrence, distant recurrence, distant
metastases, staging, pre-operative, MRI, CT,
PET, PET/CT, lymph nodes. The date of the
most recent search was January 28, 2010.
Presentation
Local and distant recurrences are usually diagnosed
within 2 years following surgery[810], during routine
follow-up investigations. Patients are mainly asympto-
matic but may present with symptoms related to the
site of the recurrence. The symptoms may be unclear
and non-specific. Extensive locoregional tumour invasion
may present with pain indicating possible nerve involve-
ment and poor prognosis.
Clinical assessment
The rectum is clinically assessed by digital examination
and endoscopy in primary cancers and in recurrent can-
cers if bowel continuity has been maintained. Digital
examination may identify luminal or extra-luminal recur-
rence and might provide information on relative fixation
to adjacent structures[11]. Endoscopy may identify intra-
luminal primary or recurrent disease and enable biopsy of
the lesion. It is essential that a full colonoscopy is per-
formed to ensure the absence of any possible synchro-
nous lesions. A hysteroscopy and/or cystoscopy may be
required to establish possible tumour invasion to the
anterior structures and provide biopsies if necessary.
Abdominal examination may reveal ascites, hepatome-
galy, enlarged lymph nodes (Sister Mary Joseph
nodule) suggestive of advanced disease.
Local staging
Accurate local staging is critical for the surgeon, as it can
provide information on the extent of the disease, the type
of surgery that would be required and the likelihood of
complete tumour resection. Endoanal ultrasonography
(EUS) has been used to diagnose recurrent disease
with adequate sensitivity and specificity[12,13] and at the
same time facilitates percutaneous biopsies. A meta-ana-
lysis demonstrated that EUS has 95% sensitivity and 98%
specificity in staging advanced (T4) rectal cancer[14].
However, it provides limited information on the extent
of the disease and cannot safely assess tumour resectabil-
ity. US has limited field of view and cannot be performed
when there is significant stenosis caused by intra-luminal
tumour or extra-luminal pressure by tumour[15]. It has
limited value following abdominoperineal excision of
the rectum (APER) but can be used transvaginally in
female patients to assess tumour invasion in the anterior
structures.
CT is the most commonly used radiologic modality for
staging primary and recurrent rectal cancer (Fig. 1a). CT
has been demonstrated to have sensitivity up to 95% in
detecting local recurrence[16,17]. However, it may often
have difficulty distinguishing disease recurrence from
tissue fibrosis[18,19] and has the tendency to overstage
bladder involvement[20]. This becomes even more diffi-
cult if radiotherapy had previously been applied or there
was previous pelvic sepsis from an anastomotic dehis-
cence[21]. Blomqvist et al.[22] demonstrated that the sen-
sitivity of CT was low in diagnosing tumour invasion
within the anterior structures (bladder and uterus; 50%)
and locoregional lymph nodes (33%). The sensitivity was
further reduced to 25% and increased to 50% following
radiotherapy.
MRI (Fig. 1b) is very valuable when staging locally
advanced primary and recurrent disease providing signif-
icant anatomic details that enable the planning of neoad-
juvant therapy and surgery[23,24]. Messiou et al.[25]
demonstrated that MRI was highly accurate in diagnos-
ing tumour invasion into individual anatomic structures
adjacent to the rectum but proved to be problematic
Figure 1 Inferior compartment tumour invasion. (a) CT
scan of low rectum. The arrow demonstrates the tumour.
(b) MRI T2-weighted signal. The arrow demonstrates the
tumour.
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when assessing the pelvic sidewalls (sensitivity¼ 70%)
and the female reproductive organs (specificity¼ 33%).
Compared with CT, MRI can more accurately differenti-
ate recurrent cancer within a presacral scar (Fig. 2),
based on differences in signal intensity between tumour
and fibrosis using T2-weighted sequences or contrast-
enhanced imaging techniques[26].
PET is an accurate diagnostic tool and may have
advantages over CT and MRI in discriminating fibrosis
from cancer (Fig. 3a)[27]. Exploiting the enhanced
uptake of fluorodeoxyglucose (FDG) by tumour cells,
PET is able to detect both local recurrence and distant
metastases. A recent meta-analysis demonstrated a PET
sensitivity and specificity of 94% for detecting local recur-
rences[28] with high accuracy in detecting pelvic recur-
rence in patients who had previously been irradiated[29].
However, limitations of PET scan include the inability to
identify small-volume disease and a relatively low sensi-
tivity for detecting lymph node metastases[30]. Mucinous
adenocarcinomas have poorer FDG uptake and therefore
can be easily missed on PET scan[31]. In an effort to
increase the confidence in diagnosing recurrence, PET
with CT (PET/CT) image fusion was performed. Sapir
et al.[32] investigated the role of PET/CT in 62 patients
and demonstrated that PET/CT was more accurate than
PET alone for detecting local recurrence but is not very
helpful in evaluating anatomic tumour changes following
chemoradiotherapy[33]. It might be useful in predicting
pathologic tumour response however (Fig. 3b)[3335].
Classifications for local disease
In an effort to establish criteria that would enable better
prediction of tumour resectability and outcome, a number
of classifications have been proposed (Table 1). The
Mayo Clinic classified local recurrence according to
points of tumour fixation and pathologic findings[36]
while Yamada et al.[37] described local recurrence by
pattern of pelvic fixation into localized, sacral, or lateral.
Other proposed classification systems[38] are based on
the UICC TNM system[39]. The Memorial Sloan
Kettering group have categorized local recurrence
based on the anatomic site of invasion by the
tumour[4042]. A new classification has been also pro-
posed based on the fascial boundaries and planes of dis-
section between intra-pelvic organs[43].
The Mayo Clinic[36] classified recurrences according
to symptoms and the degree and site of fixation. The
patients who presented without pain had better 3-year
(68.4% vs 31.6%) and 5-year (37.3% vs 26.3%) survival
Figure 3 Posterior tumour recurrence invading the
sacrum. (a) PET demonstrating increased FDG uptake
from the tumour before neoadjuvant chemoradiotherapy.
(b) PET demonstrating reduced FDG uptake from the
tumour following neoadjuvant chemoradiotherapy.
Figure 2 Posterior tumour invasion of the sacrum.
(a) MRI T2-weighted signal. (b) CT scan.
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compared with the patients who were symptomatic with
pain (p¼ 0.065). They demonstrated that patients with
more points of fixation (F13) had more complications
following surgery and had worse 3-year (35.7% vs 61.3%)
and 5-year (31.2% vs 50%) survival compared with the
patients with an F0 stage (p¼ 0.384).
Yamada et al.[37] classified local recurrence according
to the pattern of pelvic fixation. It was demonstrated that
the pattern of recurrence was a predictive factor for
5-year survival following surgery (p50.001). The 5-year
survival rate was 38%, 10% and 0% for patients with
localized, sacral invasive and lateral invasive type of
recurrence, respectively.
Wanebo et al.[38] proposed a five-stage classification
system describing intra-luminal local recurrence at the
anastomotic site as TR 1 or 2 corresponding to limited
invasion of the muscularis and full thickness penetration
of muscularis propria, respectively. TR3 described ana-
stomotic recurrences with full thickness penetration
beyond the bowel wall and into the perirectal soft
tissue. Invasion into adjacent structures/organs including
the vagina, uterus, prostate, bladder, seminal vesicles or
presacral tissues with tethering but not fixation was
described as TR4. Invasion of the bony ligamentous
pelvis including the sacrum, low pelvic/side walls, or
sacrotuberous/ischial ligaments was described as TR5.
The Memorial Sloan Kettering (MSK) group[4042]
have described a classification based on the anatomic
region of the pelvis that is involved. Local recurrence
was defined as either axial, anterior, posterior or lateral.
Axial recurrence was subdivided into anastomotic, mesor-
ectal or perirectal soft tissue, or perineum if an APER
was previously performed. Moore et al.[41] from the MSK
group demonstrated that with axial only or axial/anterior
only recurrences, the likelihood for a complete resection
was high (90% vs 43%, p50.001 and 72% vs 42%,
p¼ 0.003 respectively). The likelihood for a complete
resection was significantly reduced however when there
was a lateral recurrence (36% vs 65%, p¼ 0.002).
More recently, the authors have proposed a new
classification based on the fascial boundaries and the
anatomic planes of dissection between intra-pelvic
organs[43]. The recurrence is classified based on the
MRI findings of tumour invasion within 7 intra-pelvic
compartments (Table 1): the central, peritoneal reflec-
tion, anterior above and below the peritoneal reflection,
Table 1 Classification systems to predict tumour resectability
Study group Classification Definitions Outcomes
Mayo Clinic[36] Symptoms S0 Asymptomatic Patients who were pain-free had better
survivalS1 Symptomatic without pain
S2 Symptomatic with pain
Degree and site
of Fixation
F0 No fixation More points of fixation resulted in more
complications and worse survivalF1 Fixation to 1 point
F2 Fixation to 2 points
F3 Fixation to42 points
Yamada[37] Pattern of pelvic
fixation
Localized Invasion to adjacent pelvic organs or tissue 5-year survival of 38%
Sacral
invasive
Invasion to lower sacrum (S3, S4, S5), coccyx, periosteum 5-year survival of 10%
Lateral
invasive
Invasion to sciatic nerve, greater sciatic foramen, lateral
pelvic wall, upper sacrum (S1, S2)
5-year survival of 0%
Wanebo[38] Five stages TR1 Limited invasion of the muscularis
TR2 Full thickness penetration of muscularis propria
TR3 Anastomotic recurrences with full thickness penetration
beyond the bowel wall and into the perirectal soft tissue
TR4 Invasion into adjacent organs without fixation
TR5 Invasion of the bony ligamentous pelvis including sacrum,
low pelvic/side walls, or sacrotuberous/ischial ligaments
MSK[4042] Anatomic region
involved
Axial Anastomotic, mesorectal, perirectal soft tissue, perineum
(APER)
Axial only recurrence has 90% likelihood
of R0; lateral recurrence is associated
with 36% likelihood of R0Anterior Genitourinary tract
Posterior Sacrum and presacral fascia
Lateral Soft tissues of the pelvic sidewall and lateral bony pelvis
RMH[43] MRI; Planes of
dissection
Central Rectum or neo-rectum, intra-luminal recurrence, peri-rectal
fat or mesorectum, extra-luminal recurrence
MRI diagnosis of tumour invasion within
the lateral, posterior or in more than 2
compartments was associated with
reduced disease-free survival
PR Rectovesical pouch or recto-uterine pouch of Douglas
AA PR Ureters and iliac vessels above the peritoneal reflection,
sigmoid colon, small bowel and lateral side wall fascia
AB PR Genitourinary system
Lateral Ureters, external and internal iliac vessels, lateral pelvic
lymph nodes, sciatic nerve, sciatic notch, S1 and S2
nerve roots, piriformis or obturator internus muscle
Posterior Coccyx, presacral fascia, retro-sacral space, sacrum up to
the upper level of S1
Inferior Levator ani muscles, external sphincter complex, perineal
scar (APER), ischio-anal fossa
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posterior, lateral and inferior compartments. This is cur-
rently the classification adopted at the authors institute
to stage this group of patients. More details are shown in
Table 1.
All the classifications aim to describe the recurrent
tumour is fixed to and hence establish the potential for
and extent of resection in order to define selection crite-
ria for surgery along with prognostic information.
The authors have found the latter to be the most useful
classification enabling better communication and under-
standing between radiologists and clinicians, patient
selection for surgery and surgical planning, providing at
the same time detailed information on the extent of the
disease and signifying prognosis.
Imaging for distant metastases
Accurate identification of extrapelvic disease is key for
the decision to operate on a patient. CT and MRI have
demonstrated high sensitivity in detecting distant recur-
rence providing detailed anatomic information on the
affected organ and tumour extension into surrounding
tissues[20,44]. The accuracy of CT in detecting abdominal
disease has been demonstrated to be over 85%[20] and
MRI has similar accuracy[23,24].
A recent meta-analysis investigating the value of US,
CT, MRI and PET in detecting liver metastases (Fig. 4)
demonstrated sensitivity of 63%, 74.8%, 81.1% and
97.2%, respectively, and specificity of more than 93.8%,
Figure 4 A 1-cm focus of liver metastases in the caudate lobe medial to the inferior vena cava and lateral to the
oesophageal hiatus. (a) PET. (b) CT scan. (c) MRI. T2-weighted image on the left and T1-weighted image on the right.
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with MRI being significantly more sensitive than CT
(p¼ 0.05) and equally sensitive to PET (p¼ 0.02)[44].
There was no significant difference in the sensitivity of
PET and CT (p40.05) or between CT and US
(p¼ 0.45)[45].
PET has been demonstrated to be highly accurate in
the detection of disseminated disease[4649] and to have
significant impact on the management of patients with
suspected recurrent colorectal cancer[50,51]. A meta-ana-
lysis reported PET sensitivity of 91% and specificity of
83% for the diagnosis of distant metastases[28]. However,
the authors admitted that only 8/27 (29.6%) studies were
of high quality, fulfilling their quality criteria by at least
80%. Another study showed that the overall added value
of PET in the management of patients with local and/or
distant recurrent colorectal cancer is 8% and suggested
that PET should be used when findings remain equivocal
after serial imaging review[52]. In the authors practice, all
patients considered for a potentially curative surgical
resection undergo a PET scan to exclude disseminated
disease.
Selection criteria for surgery
The decision for surgery is made after extensive discus-
sions at the local multidisciplinary meeting and relies
heavily on the findings of the available diagnostic mod-
alities. It is the radiologic findings that will determine the
tumour resectability. Therefore accurate preoperative
staging can help to establish the extent of local disease
and the presence or absence of distant metastases, which
is imperative when considering patients for exenterative
surgery for locally advanced primary or recurrent rectal
cancer.
Distant recurrence
The presence of distant metastases is normally consid-
ered as a contraindication for exenterative surgery for
locally advanced primary or recurrent rectal cancer[53].
It has been demonstrated by some centres however that
synchronous or staged resection of locoregional recur-
rence and distant metastases can have acceptable results
in a select group of patients[5456]. However, it is gener-
ally contraindicated due to the significant morbidity that
may be associated with this type of procedure[37,38,5759].
Resectable local recurrence
In the absence of distant disease, surgical resection of the
primary cancer or the locoregional recurrence is the only
potentially curative option. Surgery for advanced primary
or recurrent rectal cancer includes a range of different
procedures that depend on the extent of the disease and
the specific organs/structures that are involved. Surgery
is performed en bloc and is considered curative when the
resection margins are free of microscopic disease
(R0 resection). Microscopic and macroscopic residual
disease at the resection margins are defined as R1 and
R2 resection, respectively. It has been previously demon-
strated that R1 or R2 resection can result in poorer sur-
vival[7,36,60,61] and consequently it should be considered
as palliative resection with considerable morbidity.
Therefore the identification of patients who can poten-
tially achieve an R0 resection is crucial and extremely
difficult. Preoperative imaging with PET, CT and MRI
and clinical assessment are utilized in an effort to opti-
mize the selection of patients in whom curative resection
is considered possible as well as those in whom resection
is contraindicated.
Contraindications for surgical resection
It is essential to assess the patients fitness for surgery
before discussing surgery with the patient because the
lack of fitness could be a contraindication of its own
when undergoing such a major procedure. Surgery is
contraindicated in the presence of circumferential or
extensive lateral pelvic side wall involvement, involve-
ment of the iliac vessels, bilateral ureteric obstruction,
sciatic nerve involvement and periaortic lymph node
metastases[53,54,6264]. Involvement of the iliac vessels
may present with lower limb oedema whereas ureteric
obstruction presents with hydronephrosis. Tumour inva-
sion of the sciatic nerve may present with lower limb pain
and weakness. Limited tumour invasion to the lateral
pelvic wall and invasion of the sacrum above the S2 ver-
tebrae are considered relative contraindications since
there are surgical options in both cases[38,57,65] but the
likelihood of complete resection is very low.
Irresectable local recurrence
Surgical resection and chemoradiotherapy can be used
for palliation alleviating the patients symptoms that are
related to the organs/structure that are invaded by
tumour. It has been suggested that palliative resection
can have an improvement in quality of life and pain
relief[66,67]. However, the co-morbidities related with
this type of surgery must also be considered[68]. It is
therefore important that the patients are carefully
selected for palliative procedures taking into consider-
ation possible co-morbidities and their social circum-
stances, because the benefits from these procedures are
short term. Symptomatic relief can last up to 17 months
with a median symptom-free interval of 4 months com-
pared with 23 months for non-palliative procedures
(p50.001)[69].
Discussion
The present review demonstrates the important contribu-
tion that a radiologist might have in the decision making
for patients under consideration for exenterative pelvic
surgery for recurrent colorectal pelvic cancer. The main
objective in this process is to filter the patients who
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would most benefited from surgery by achieving com-
plete tumour resection. The process of selecting the
patients who should undergo surgery or best medical
therapy is guided by the discussions within the multidis-
ciplinary meetings. In these meetings, radiologists carry a
key role as the ultimate decision for surgery or palliative
care usually rests with them. This is why a number of
radiologic modalities are used with the aim of maximiz-
ing the information provided and therefore a better
informed decision for further management can be made.
The role of CT and MRI scans is to stage the extent of
local disease within the pelvis. More recently, EUS has
been used to identify local recurrence and the local extent
of the disease. Diffusion-weighted MRI, which has also
been used in recent years, may provide additional infor-
mation on the extent of the disease but its role is still
unclear and is not validated due to the absence of
substantial evidence regarding its diagnostic accuracy.
PET/CT and CT scans are used to filter patients with
evidence of distant metastases. When there is doubt and
controversial findings among the different radiologic
modalities, laparoscopy might be used to clarify the pres-
ence of distant metastases. The use of all these modalities
is evidence of the fundamental role that radiologists
have in the management of patients who are considered
for exenterative surgery for recurrent colorectal pelvic
cancer.
Accurate preoperative staging is crucial for the man-
agement of the patients with locally advanced primary
and recurrent rectal cancer. It can provide the necessary
information to make decisions on tumour resectability
and type of surgery required to achieve complete resec-
tion. CT, MRI and PET all have a place in the preoper-
ative staging of these patients. In the authors practice,
MRI is used to plan surgery as it can provide anatomic
details; CT and PET are mostly used to exclude distant
metastases. Radiotherapy and previous surgery can
reduce the accuracy of all the diagnostic modalities and
this needs to be taken into consideration when interpret-
ing scans following radiotherapy. Therefore, adequate
training and experience in interpreting these images is
required so that the radiologists can maximize their con-
tribution in the management of this group of patients.
Further good quality prospective studies are needed to
better identify patient selection criteria for surgery, to
enhance the oncologic outcome and the improve the
patients quality of life.
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